Department of Microbiology, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.
Student Research Committee, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.
Microb Drug Resist. 2019 Nov;25(9):1330-1337. doi: 10.1089/mdr.2018.0457. Epub 2019 Jul 10.
Antibiotic resistance is an increasing phenomenon and has become a serious public health concern. Nowadays, limited therapeutic options exist for the treatment of invasive infections caused by drug-resistant strains, particularly methicillin-resistant (MRSA). The present study was conducted to analyze the published literature on the activity of tedizolid toward MRSA strains. A systematic literature search was conducted on the Web of Science, PubMed, Scopus, and Google Scholar electronic databases from January 2000 to December 2017 to cover all published articles relevant to our study. Then, 18 publications that met our inclusion criteria were selected for data extraction and analysis by the Comprehensive Meta-analysis software. The overall antibacterial activity of tedizolid on 10,119 MRSA isolates was estimated 0.25 and 0.5 μg/mL for MIC and MIC (minimum inhibitory concentration at which 50% and 90% of isolates were inhibited, respectively), respectively. The pooled prevalence of tedizolid susceptibility was estimated at 99.6% (95% confidence interval: 99.5-99.8%). Only 4 of 18 included publications have reported the antibacterial activity of tedizolid against linezolid-resistant isolates, of which the MIC range of tedizolid was 0.25-16 μg/mL. Of the four studies, all of the linezolid-resistant isolates were susceptible to tedizolid in one study, and in the other studies, the susceptibility rates were <50%. Based on the results of the systematic reviews, tedizolid had a promising antibacterial activity against MRSA isolates from different clinical sources. However, future studies are needed to provide clinical evidence to support these observations.
抗生素耐药性是一个日益严重的现象，已成为严重的公共卫生关注问题。如今，对于治疗耐药菌株引起的侵袭性感染，特别是耐甲氧西林金黄色葡萄球菌（MRSA），治疗选择有限。本研究旨在分析已发表的关于替加环素对 MRSA 菌株活性的文献。通过 Web of Science、PubMed、Scopus 和 Google Scholar 电子数据库，从 2000 年 1 月至 2017 年 12 月进行了系统的文献检索，以涵盖与本研究相关的所有已发表文章。然后，使用 Comprehensive Meta-analysis 软件选择符合纳入标准的 18 篇出版物进行数据提取和分析。替加环素对 10119 株 MRSA 分离株的总体抗菌活性估计分别为 MIC（最低抑菌浓度，抑制 50%和 90%分离株的浓度）和 MIC（最低抑菌浓度在 50%和 90%的分离株被抑制的浓度）为 0.25 和 0.5μg/mL。替加环素敏感性的汇总流行率估计为 99.6%（95%置信区间：99.5-99.8%）。只有 18 篇纳入文献中的 4 篇报道了替加环素对利奈唑胺耐药分离株的抗菌活性，其中替加环素的 MIC 范围为 0.25-16μg/mL。在这四项研究中，一项研究中所有利奈唑胺耐药分离株均对替加环素敏感，而在另外两项研究中，敏感性率<50%。基于系统评价的结果，替加环素对来自不同临床来源的 MRSA 分离株具有有前景的抗菌活性。然而，需要进一步的研究提供临床证据来支持这些观察结果。
